ClinicalTrials.gg
RecruitingNCT06053567STEP3Updated May 15, 2026

Community-based Smoking Cessation Treatment for Adults With High Stress Sensitivity.

A Phase 3 interventional study of Aerobic Exercise and Counseling in Nicotine Dependence, sponsored by Jasper A. Smits. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Jasper A. Smits · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies testing Nicotine Patch in Tobacco Use Disorder — 4 open to participants now, 5 under way, 2 of them phase 3. Nicotine Patch · Tobacco Use Disorder.

Planned enrollment
13th of 42
360 · median 135
Started
2023
with 1 other
Phase 3
5 of 42
1 open now
Registered
41st of 42
by date

Among the 42 studies testing Nicotine Patch in Tobacco Use Disorder, this one is the 13th largest by planned enrollment, is one of 2 that started in 2023, is one of 5 in phase 3, and was the 41st registered.

Tobacco Use Disorder

1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

Browse Tobacco Use Disorder studies →

Open to participants now

4 of the 42 studies testing Nicotine Patch in Tobacco Use Disorder are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Nicotine Patch

Nicotine Patch: first FDA approval 1991 (NICODERM CQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing Nicotine Patch in Tobacco Use Disorder, or all of them as a file.
02

Study summary

Anxiety sensitivity, reflecting the fear of bodily sensations, is a risk factor for the maintenance and relapse of smoking. This study is designed to address the question - is a smoking cessation intervention personalized to high anxiety sensitive smokers and adapted for implementation by the YMCA effective among racially/ethnically diverse samples?

Read the detailed description

This protocol provides the recommended treatment to achieve smoking cessation (i.e., counseling and nicotine replacement therapy) and randomly assigns individuals to a high-intensity exercise or low-intensity exercise intervention as a strategy to engage the mechanisms relevant to high anxiety sensitive smokers to improve smoking cessation outcomes.

03

Conditions studied

  • Nicotine Dependence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (age ≥ 18);
  • High Anxiety Sensitivity (≥5 on the Short Scale Anxiety Sensitivity Index [SSASI]);
  • Daily smoker, ≥5 cigarettes (including e-cigarettes, little cigars/cigarillos) for ≥1 year;
  • Motivated to quit smoking as evidenced by a score of ≥5 on a 0-10 Likert scale;
  • \< 40;
  • Medical clearance to participate.
  • Located near a participating YMCA site (within 50 miles)

Exclusion criteria

Exclusion Criteria:

  • Regular exercise defined as engaging in vigorous-intensity exercise for at least 75 minutes per week for the last 3 months
  • Receiving current intervention for smoking cessation.
  • Outstanding debt to the YMCA
  • Listed as a sex offender on the National Sex Offender Registry
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    High-Intensity Aerobic Exercise

    Participants assigned to this arm will be instructed to complete 75 minutes per week of aerobic training at 60-85% of the their heart rate reserve.

    Behavioral: Aerobic Exercise · Behavioral: Counseling · Drug: Nicotine patch

  • Active comparator
    Low-Intensity Aerobic Exercise

    Participants assigned to this arm will be instructed to complete 75 minutes per week of aerobic training at 20-40% of the their heart rate reserve.

    Behavioral: Aerobic Exercise · Behavioral: Counseling · Drug: Nicotine patch

Interventions

  • BehavioralAerobic Exercise

    Participants will select a YMCA branch and will be assigned a personal fitness instructor who will oversee a 15-week exercise intervention. The weekly exercise prescription is 75 minutes of aerobic training.

  • BehavioralCounseling

    Participants will receive the standard tobacco cessation package of up to 5 proactive interactions from the Texas Tobacco Quitline (TTQ). Interactions are typically phone calls, but can be chat or live text if the participant prefers. Interaction 1 is for assessment and quit date planning, Interaction 2 occurs prior to the quit date and can be a group session, Interaction 3 occurs shortly following the quit date, and Interactions 4 and 5 are for relapse prevention if the smoker has quit or problem solving if they have not quit. TTQ also offers a tobacco cessation text messaging program and access to a web portal with a variety of cessation resources.

  • On the target quit day (week 6), participants will be provided 8 weeks of nicotine replacement therapy (24-hour transdermal nicotine patches \[TNP\]).

06

What researchers measure

Primary outcomes

  1. 7-day point prevalence abstinence (PPA) at 6-month follow-up

    Self-report of no smoking (not even a puff) during the previous 7 days, verified by expired carbon monoxide (CO; ≤5ppm), saliva cotinine (\<30 ng/mL), or significant other, and not invalidated by any of these verification measures. Failure to provide any of these 3 verification measures will result in PPA being considered missing.

    Time frame: Protocol week 30, which is 24 weeks (6 months) after the quit attempt (set at week 6)

Secondary outcomes

  1. 7-day point prevalence abstinence (PPA) at 12-month follow-up

    Self-report of no smoking (not even a puff) during the previous 7 days, verified by expired carbon monoxide (CO; ≤5ppm), saliva cotinine (\<30 ng/mL), or significant other, and not invalidated by any of these verification measures. Failure to provide any of these 3 verification measures will result in PPA being considered missing.

    Time frame: Protocol week 54, which is 48 weeks (12 months) after the quit attempt (set at week 6)

  2. 7-day point prevalence abstinence (PPA) at 9-month follow-up

    Self-report of no smoking (not even a puff) during the previous 7 days, verified by expired carbon monoxide (CO; ≤5ppm), saliva cotinine (\<30 ng/mL), or significant other, and not invalidated by any of these verification measures. Failure to provide any of these 3 verification measures will result in PPA being considered missing.

    Time frame: Protocol week 42, which is 36 weeks (9 months) after the quit attempt (set at week 6)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Within one year of completion (publication) of the primary aims for this project, we will provide de-identified data from this project to interested researchers. The data are to be provided in a SPSS file or Excel, with separate documentation of labels/characteristics for each column of data. Data will be released directly by Dr. Smits's team at UT to investigators providing evidence of their institution's IRB approval for planned analyses of the data.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Within one year of completion (publication) of the primary aims. No end date.

Access criteria: Data will be released directly by Dr. Smits's team at UT to investigators providing evidence of their institution's IRB approval for planned analyses of the data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Mar 2029, 63 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2023
First posted
Sep 25, 2023
StartActual
Dec 27, 2023
Primary completionEst.
Mar 31, 2029
CompletionEst.
Jun 30, 2029
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06053567
Lead sponsor
Jasper A. Smits
Responsible party
Jasper A. Smits (Principal Investigator, University of Texas at Austin) — Sponsor-investigator
First posted
Sep 25, 2023
Start date
Dec 27, 2023
Primary completion
Mar 31, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
May 15, 2026

Study contacts

Marla I Sarmiento, BS
Contact
sarmimar@utexas.edu
915-502-9979
Jasper Smits, PhD
principal investigator · University of Texas at Austin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nicotine Patch

Start the discussion